InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,988.64
(
0.08%
)
US TECH 100
20,449.20
(
-0.33%
)
Dow Jones
44,040.39
(
0.29%
)
Brent Oil
72.09
(
0.65%
)
Bitcoin
93,142.49
(
5.93%
)
Post# of 253587
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: DewDiligence post# 17598

Friday, 10/28/2005 11:41:37 PM

Friday, October 28, 2005 11:41:37 PM

Post# of 253587
Reopro

This result is interesting but unsuprising, given the long half-life of ReoPro (~11 hours, I believe, but I'm too lazy to look it up right now) and its relative propensity to cause severe thrombocytopenia. Just as a guess, I think Integrilin may confer benefit in stroke patients because it has a substantially lower rate of thrombocytopenia; moreover, it has a relatively short half life so if issues do develop platelet activity can be rapidly restored upon discontinuation.

John




Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up